{"id":"W2908242089","doi":"10.1016/j.jpsychires.2019.01.003","title":"Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study","year":2019,"lang":"en","type":"article","venue":"Journal of Psychiatric Research","topic":"Treatment of Major Depression","field":"Medicine","cited_by":340,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Fusion Oriented REsearch for disruptive Science and Technology; Janssen Biotech; Canadian Institutes of Health Research; Agency for Healthcare Research and Quality; Allergan; National Institutes of Health; Rogers Family Foundation; Assurex Health; National Institute of Mental Health; Pfizer; LivaNova; Ontario Brain Institute; Patient-Centered Outcomes Research Institute; Avanir Pharmaceuticals; Stanley Medical Research Institute; ACADIA Pharmaceuticals; Alkermes; Acadia University; Bristol-Myers Squibb; Otsuka America; Biogen","keywords":"Medicine; Randomized controlled trial; Major depressive disorder; Pharmacogenomics; Depression (economics); Hamilton Rating Scale for Depression; Rating scale; Clinical trial; Internal medicine; Psychiatry; Physical therapy; Psychology; Mood; Pharmacology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09006789581775537,"score_gpt":0.5069060345876394,"score_spread":0.416838138769884,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}